Utilization of DEPArray in molecular pathology for clinical diagnostics and translational research  
Menarini Silicon Biosystems Logo
October 24, 2019
1 pm to 2 pm EDT



Webinar Description:

This webinar explores the research of Dr. Matija Snuderl, who uses Menarini Silicon Biosystem's novel FFPE (Formalin Fixed Paraffin Embedded) kit and DEPArray cell sorting system to isolate single cells from archived patient samples. Dr. Snuderl has incorporated the DEPArray into a New York state clinically validated assay for genomic analysis. The webinar will also highlight his research in the area of liver metastases and the study of heterogeneous cancer cell populations on a single cell level, starting with the FFPE kit for disaggregation, the DEPArray for cell imaging and sorting, the VRNxT™ instrument for automated supernatant aspiration, and whole genome amplification workflows using MSB’s Ampli1 WGA kits.

Learning Objectives:

  • ease of use of FFPE kit for isolation of single cells
  • precision and accuracy in single cell isolation and recovery using the DEPArray cell sorting and imaging system
  • ability to safely centrifuge and wash cells using the VR NxT instrument for volume reduction after centrifugation


Dr. Matija Snuderl, MD
Associate Professor, Department of Pathology; Director, Molecular Pathology. Pathology Department
NYU Langone Health

Since medical school, I developed a passion for analyzing disease, specifically cancer. This led me to specialize in neuropathology, the study of nervous system diseases. As a neuropathologist at NYU Langone, I diagnose brain tumors and other brain diseases in children and adults. As director of molecular pathology, I oversee molecular and genomic profiling, a laboratory method that allows our team to accurately diagnose all types of brain tumors. My clinical research focuses on identifying novel biomarkers for diagnosis and therapy. My laboratory at NYU Langone studies cancer genetics, genenetic heterogeneity and epigenetics and examines the molecular differences between tumors at the cellular level. Our team discovered several novel molecularly defined subtypes of brain tumors and contributed to the development of DNA methylation–based classification of brain tumors, an approach that uses machine learning and epigenetic signatures to more effectively diagnose brain tumors. Our laboratory is the first in the United States to provide this test to people with brain tumors. I am a member of several professional societies, including the American Association for the Advancement of Science and the American Association of Neuropathologists. I also received the Lucien Rubinstein Award for my research in neuro-oncology.


Cost: No Cost!